Updated labeling for injectable haloperidol: hear about the FDA's revised warnings for prescribing haloperidol to avoid QT prolongation.
References and Resources
NDA 20-919 (Haloperidol). QT Prolongation in Association with the Use of Haloperidol Decanoate: a Response to the Pharmacovigilance Department of the Italian Drug Agency. Prepared by Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
Click Here to view FDA alert.
Sponsored by The Doctor's Channel